Benefits of a modified local precision liver resection using intraoperative laparoscopic ultrasound in the treatment and prognosis of patients with liver cancer.
Author:
Xu Yansong1ORCID, Shen Lin2ORCID
Affiliation:
1. Department of Hepatobiliary Surgery, Affiliated Hospital of Beihua University, Jilin, China. 2. Department of Anesthesiology, Affiliated Hospital of Beihua University, Jilin, China.
Abstract
Abstract. The incidence and mortality rate of liver cancer has increased significantly. Recently, intraoperative laparoscopic ultrasound (LUS) has been used in hepatectomy, in addition to open liver resection, as the most common treatment method. The current research aims to address this issue. Seventy-six patients with liver cancer who were admitted to the Hospital of Beihua Univer-sity from February 2018 to September 2021 were randomly divided into two groups of 38 patients, one group undergoing conventional laparoscopic sur-gery (control group) and the other group undergoing a precise laparoscopic liver resection after placing an intraoperative LUS instrument (study group). Blood loss and hepatic vein damage during surgery were less in the study group (p<0.05). Seven days after surgery, liver function indices (albumin, total bil-irubin, and alanine and aspartate aminotransferases) and indices related to immune function interleukin 6, tumor necrosis factor α, CD3+ and CD4+ T lymphocytes and NK cells level in the study group improved compared to the control group. The postoperative complications were less in the study group, and the nine-month follow-up showed that the recurrence rate was lower and the survival rate was higher in this group. This study shows that precise laparo-scopic hepatectomy modified with the use of intraoperative laparoscopic ultra-sound results in better intraoperative and postoperative outcomes for the prog-nosis and survival rate of patients with liver cancer, which makes this surgical technique worth generalizing in clinical practice.
Publisher
Universidad del Zulia
Reference34 articles.
1. Wei Q, Zhou H, Hou X, Liu X, Chen S, Huang X, Chen Y, Liu M, Duan Zh. Current status of and barriers to the treatment of advanced-stage liver cancer in China: a questionnaire-based study from the perspective of doctors. BMC Gastroenterol 2022; 351. https://doi.org/10.1186/s12876-022-02425-4. 2. Sun H C, Zhou J, Wang Z, Liu X, Xie Q, Jia W, Zhao M, Bi X, Li G, Bai X, Ji Y, Xu L, Zhu X D, Bai D, Chen Y, Chen Y, Dai Ch, Guo R, Guo W, Hao Ch, Huang T, Huang Zh, Li D, Li Gang, Li Tao, Li X, Li G, Liang X, Liu J, Liu F, Lu Sh, Lu Zh, Lv W, Mao Y, Shao G, Shi Y, Song T, Tan G, Tang Y, Tao K, Wan Ch, Wang G, Wang L, Wang Sh, Wen T, Xing B, Xiang B, Yan Sh, Yang D, Yin G, Yin T, Yin Zh, Yu Zh, Zhang B, Zhang J, Zhang Sh, Zhang T, Zhang Y, Zhang Y, Zhang A, Zhao H, Zhou L, Zhang W, Zhu Zh, Qin Sh, Shen F, Cai X, Teng G, Cai J, Chen M, Li Q, Liu L, Wang W, Liang T, Dong J, Chen X, Wang X, Zheng Sh, Fan J. Chinese expert consensus on conversion therapy for hepatocellular carcinoma. Hepatobiliary Surge Nutr 2021; 11(2): 227–252. https://doi.org/10.21037/hbsn-21-328. 3. Sasaki K, Ruffolo LI, Kim MH, Fujili M, Hashimoto K, Imaoka Y, Melcher M L, MD, Aucejo F N, Tomiyama K, Hernandez-Alejandro R. The current state of liver transplantation for colorectal liver metastases in the United States: A call for standardized reporting. Ann Surg Oncol 2023; 30: 2769–2777. https://doi.org/10.1245/s10434-023-13147-6. 4. Sena G, Paglione D, Gallo G, Goglia M, Osso M, Nardo B. Surgical resection of a recurrent hepatocellular carcinoma with portal vein thrombosis: is it a good treatment option? A case report and systematic review of the literature. J Clin Med 2022; 11(18):5287. 5. Shannon AH, Ruff SM, Pawlik TM. Expert insights on current treatments for hepatocellular carcinoma: clinical and molecular approaches and bottlenecks to progress. J Hepatocell Carcinoma 2022; 9:1247-1261. https://doi.org/10.2147/JHC.S383922.
|
|